MCRB - Seres Therapeutics, Inc.
Pre-Market:
| Previous Close | 4.7400 |
| Open | 4.7300 |
| Bid | 4.7900 x 4000 |
| Ask | 4.8800 x 1000 |
| Day's Range | 4.6500 - 4.8750 |
| 52 Week Range | 2.5000 - 9.4900 |
| Volume | |
| Avg. Volume | 3,013,655 |
| Market Cap | 608.809M |
| Beta (5Y Monthly) | 2.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 0% and 126.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Investing.com
Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more
By Vlad Schepkov
- Simply Wall St.
Seres Therapeutics, Inc. (NASDAQ:MCRB) down to US$623m market cap, but institutional owners may not be as affected after a year of 3.1% returns
Key Insights Significantly high institutional ownership implies Seres Therapeutics' stock price is sensitive to their...
- Zacks
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Reuters
UPDATE 2-US FDA approves Seres Therapeutics' pill for deadly C. difficile infections
The U.S. health regulator on Wednesday approved Seres Therapeutics Inc's pill for treating a type of bacterial infection, giving an easier and standardized option to patients who often have to rely on individual donors for fecal transplants. The drug, branded as Vowst, was approved for treating 18 years and older for recurrent Clostridioides difficile (C. diff) infections (CDI), generally caused by prolonged use of antibiotics, which wipe out friendly colon bacteria and can cause potentially fatal diarrhea and inflammation of the colon. Vowst consists of a certain kind of bacteria made by purifying fecal matter derived from healthy people, while fecal transplants are donated by healthy volunteers and are not purified.
- Zacks
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Investing.com
Weekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro Recap
By Vlad Schepkov
- Motley Fool
Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon
After a dreadful 2022, growth stocks have started to rebound in 2023. The tech-heavy Nasdaq Composite has gained a healthy 15.4% so far this year. For example, Wall Street analysts think small-cap biotechs Iovance Biotherapeutics (NASDAQ: IOVA) and Seres Therapeutics (NASDAQ: MCRB) could see a parabolic rise in their respective share prices in 2023.
- Zacks
Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?
Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Motley Fool
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts.
- Zacks
Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Thomson Reuters StreetEvents
Q4 2022 Seres Therapeutics Inc Earnings Call
Q4 2022 Seres Therapeutics Inc Earnings Call
- Zacks
Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Seres Therapeutics' (NASDAQ:MCRB) investors will be pleased with their respectable 70% return over the last three years
The last three months have been tough on Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders, who have seen the share...
- Simply Wall St.
Seres Therapeutics Third Quarter 2022 Earnings: Misses Expectations
Seres Therapeutics ( NASDAQ:MCRB ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.44m (down 97% from 3Q...
- Zacks
Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.89% and 71.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Calculating The Intrinsic Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)
In this article we are going to estimate the intrinsic value of Seres Therapeutics, Inc. ( NASDAQ:MCRB ) by taking the...
- Simply Wall St.
Analysts Are Betting On Seres Therapeutics, Inc. (NASDAQ:MCRB) With A Big Upgrade This Week
Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders will have a reason to smile today, with the analysts making...
- Zacks
Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -20.69% and 79.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Do Institutions Own Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares?
Every investor in Seres Therapeutics, Inc. ( NASDAQ:MCRB ) should be aware of the most powerful shareholder groups...
- Simply Wall St.
Seres Therapeutics (NASDAQ:MCRB shareholders incur further losses as stock declines 12% this week, taking one-year losses to 87%
It's not a secret that every investor will make bad investments, from time to time. But it should be a priority to...
